Correction to Lancet Diabetes Endocrinol 2024; 12: e2–11

IF 44 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

The Lancet Diabetes & Endocrinology Pub Date : 2025-03-05 DOI:10.1016/s2213-8587(25)00056-7

引用次数: 0

Abstract

Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol 2024; 12: e2–11—The appendix of this Article has been corrected as of March 5, 2025.

查看原文本刊更多论文

《柳叶刀糖尿病内分泌》2024版修正；12: e2-11

新兴风险因素合作/EPIC-CVD/维生素D研究合作。估计维生素D与冠心病、中风和全因死亡率的剂量反应关系：观察性和孟德尔随机化分析柳叶刀糖尿病内分泌杂志2024；[12:e2 - 11]本文附录已于2025年3月5日更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Lancet Diabetes & Endocrinology ENDOCRINOLOGY & METABOLISM-

CiteScore

61.50

自引率

1.60%

发文量

371

期刊介绍： The Lancet Diabetes & Endocrinology, an independent journal with a global perspective and strong clinical focus, features original clinical research, expert reviews, news, and opinion pieces in each monthly issue. Covering topics like diabetes, obesity, nutrition, and more, the journal provides insights into clinical advances and practice-changing research worldwide. It welcomes original research advocating change or shedding light on clinical practice, as well as informative reviews on related topics, especially those with global health importance and relevance to low-income and middle-income countries. The journal publishes various content types, including Articles, Reviews, Comments, Correspondence, Health Policy, and Personal Views, along with Series and Commissions aiming to drive positive change in clinical practice and health policy in diabetes and endocrinology.